^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Jemperli (dostarlimab-gxly) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5135 - Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial
Published date:
03/09/2022
Excerpt:
GARNET (NCT02715284) is a phase 1, multicenter, open-label, single-arm study of dostarlimab in pts with advanced/recurrent solid tumors….Objective response rate (ORR) was higher in pts with TMB-H/PDL1-H tumors (55.6% for all cohorts, combined....
Trial ID:
